Ceftazidime-Avibactam Susceptibility Breakpoints Against Enterobacteriaceae and Pseudomonas Aeruginosa
Antioxidants（2018）SCI 2区SCI 1区
AstraZeneca | Wright Dose Ltd | Allergan Plc
Abstract
Clinical susceptibility breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa for the ceftazidime-avibactam dosage regimen of 2,000/500 mg every 8 h (q8h) by 2-h intravenous infusion (adjusted for renal function) have been established by the FDA, CLSI, and EUCAST as susceptible (MIC, ≤8 mg/liter) and resistant (MIC, >8 mg/liter). The key supportive data from pharmacokinetic/pharmacodynamic analyses, in vitro surveillance, including molecular understanding of relevant resistance mechanisms, and efficacy in regulatory clinical trials are collated and analyzed here.
MoreTranslated text
Key words
MIC breakpoints,ceftazidime-avibactam
PDF
View via Publisher
AI Read Science
AI Summary
AI Summary is the key point extracted automatically understanding the full text of the paper, including the background, methods, results, conclusions, icons and other key content, so that you can get the outline of the paper at a glance.
Example
Background
Key content
Introduction
Methods
Results
Related work
Fund
Key content
- Pretraining has recently greatly promoted the development of natural language processing (NLP)
- We show that M6 outperforms the baselines in multimodal downstream tasks, and the large M6 with 10 parameters can reach a better performance
- We propose a method called M6 that is able to process information of multiple modalities and perform both single-modal and cross-modal understanding and generation
- The model is scaled to large model with 10 billion parameters with sophisticated deployment, and the 10 -parameter M6-large is the largest pretrained model in Chinese
- Experimental results show that our proposed M6 outperforms the baseline in a number of downstream tasks concerning both single modality and multiple modalities We will continue the pretraining of extremely large models by increasing data to explore the limit of its performance
Try using models to generate summary,it takes about 60s
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Related Papers
Dual Β-Lactam Combinations Highly Active Against Mycobacterium Abscessus Complex in Vitro
mBio 2019
被引用53
Antimicrobial Agents and Chemotherapy 2019
被引用50
Clinical Microbiology Reviews 2019
被引用497
Selecting the dosage of ceftazidime–avibactam in the perfect storm of nosocomial pneumonia
European Journal of Clinical Pharmacology 2019
被引用8
Antimicrobial Agents and Chemotherapy 2020
被引用17
Journal of Chemotherapy 2020
被引用4
Journal of Chemotherapy 2021
被引用1
Pathogens 2021
被引用12
Infectious Diseases and Therapy 2021
被引用13
Antibiotics 2021
被引用7
Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas Aeruginosa
Antibiotics 2021
被引用31
Clinical Pharmacology & Therapeutics 2021
被引用10
The Primary Pharmacology of Ceftazidime/avibactam: in Vitro Translational Biology.
Journal of Antimicrobial Chemotherapy 2022
被引用7
The Primary Pharmacology of Ceftazidime/avibactam: Resistance in Vitro
The Journal of antimicrobial chemotherapy 2023
被引用4
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY 2023
被引用0
Pharmaceutics 2024
被引用0
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY 2024
被引用0
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn
Chat Paper
GPU is busy, summary generation fails
Rerequest